insights_auto
Why is CRSP up 5.30%?
Dive Deeperchevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
$53.12
arrow_upward
+5.30%(+2.68) 1D
Oct 9, 11:54:32 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CRSP...
Open
$50.82
High
$53.60
Low
$50.52
Mkt. cap
5.14B
Avg. vol.
1.62M
Volume
633.38K
52-wk high
$78.00
52-wk low
$44.12
EPS
-$4.76
Beta
1.45
Shares outstanding
96.69M
No. of employees
393
Open
$50.82
High
$53.60
Low
$50.52
Mkt. cap
5.14B
Avg. vol.
1.62M
Volume
633.38K
52-wk high
$78.00
52-wk low
$44.12
EPS
-$4.76
Beta
1.45
Shares outstanding
96.69M
No. of employees
393
News stories
From web sources and news partners
The Motley Fool
·
1 hour ago
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
Zacks
·
2 hours ago
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
Investing.com UK
·
4 hours ago
H.C. Wainwright reiterates Buy on CRISPR stock, $80 target By Investing.com
MarketBeat
·
9 hours ago
CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Rated "Moderate Buy" by Sell-Side Brokerages
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG
CEOSamarth Kulkarni
Employees393
Founded2013
HeadquartersZug, Zug, Switzerland
SectorBiotechnology
Websitecrisprtx.com